Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

DermTech, Inc. (NASDAQ:DMTK) Forecasted to Earn Q3 2022 Earnings of ($0.98) Per Share

Defense World ·  {{timeTz}}

DermTech, Inc. (NASDAQ:DMTK – Get Rating) – Equities research analysts at Oppenheimer boosted their Q3 2022 earnings per share estimates for shares of DermTech in a report released on Tuesday, August 16th. Oppenheimer analyst F. Brisebois now forecasts that the company will earn ($0.98) per share for the quarter, up from their previous estimate of ($1.06). Oppenheimer has a "Outperform" rating and a $23.00 price objective on the stock. The consensus estimate for DermTech's current full-year earnings is ($4.02) per share. Oppenheimer also issued estimates for DermTech's Q4 2022 earnings at ($0.97) EPS, FY2022 earnings at ($3.95) EPS, Q1 2023 earnings at ($1.02) EPS, Q2 2023 earnings at ($0.85) EPS, Q3 2023 earnings at ($0.85) EPS, Q4 2023 earnings at ($0.84) EPS and FY2023 earnings at ($3.53) EPS.

Get DermTech alerts:

A number of other brokerages have also weighed in on DMTK. Craig Hallum decreased their price objective on DermTech from $37.00 to $18.00 in a report on Tuesday, August 9th. BTIG Research cut their target price on DermTech from $19.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, August 15th. Lake Street Capital cut their target price on DermTech from $34.00 to $14.00 in a research note on Tuesday, August 9th. Finally, Cowen cut their target price on DermTech from $33.00 to $20.00 in a research note on Wednesday, May 4th.

DermTech Price Performance

Shares of NASDAQ:DMTK opened at $5.71 on Friday. The business's 50 day moving average price is $6.47 and its 200-day moving average price is $9.37. The firm has a market capitalization of $171.53 million, a price-to-earnings ratio of -1.60 and a beta of 1.40. DermTech has a 1 year low of $4.18 and a 1 year high of $38.97.

Institutional Trading of DermTech

A number of hedge funds and other institutional investors have recently modified their holdings of DMTK. Financial Management Professionals Inc. purchased a new position in DermTech during the 2nd quarter valued at about $26,000. Wolverine Asset Management LLC purchased a new position in DermTech during the 4th quarter valued at about $43,000. Wedbush Securities Inc. purchased a new position in DermTech during the 2nd quarter valued at about $58,000. Amalgamated Bank purchased a new position in DermTech during the 1st quarter valued at about $58,000. Finally, Valeo Financial Advisors LLC purchased a new position in shares of DermTech in the 2nd quarter valued at about $60,000. 75.12% of the stock is owned by institutional investors and hedge funds.

About DermTech

(Get Rating)

DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.

Further Reading

  • Get a free copy of the StockNews.com research report on DermTech (DMTK)
  • 2 EV Suppliers Powering To Gains After Raising Views
  • Applied Materials Results Show A Slowing Semiconductor Market
  • MarketBeat: Week in Review 8/15 – 8/19
  • Near-Term Headwinds Present An Opportunity In Ross Stores
  • Apple's Stock Could Be On The Verge Of Another 30% Rally

Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.